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Abstract
Rationale: The monitoring of TB treatments in clinical practice and clinical trials relies on 
traditional sputum-based culture status indicators at specific time points. Accurate, predictive, 
blood-based protein markers would provide a simpler and more informative view of patient health 
and response to treatment.
Objective: We utilized sensitive, high throughput multiplexed ion mobility-mass spectrometry 
(IM-MS) to characterize the serum proteome of TB patients at the start of and at 8 weeks of 
rifamycin-based treatment. We sought to identify treatment specific signatures within patients as 
well as correlate the proteome signatures to various clinical markers of treatment efficacy.
Methods: Serum samples were collected from 289 subjects enrolled in CDC TB Trials 
Consortium Study 29 at time of enrollment and at the end of the intensive phase (after 40 doses of 
TB treatment). Serum proteins were immunoaffinity-depleted of high abundant components, 
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digested to peptides and analyzed for data acquisition utilizing a unique liquid chromatography 
IM-MS platform (LC-IM-MS). Linear mixed models were utilized to identify serum protein 
changes in the host response to antibiotic treatment as well as correlations with culture status end 
points.
Results: A total of 10,137 peptides corresponding to 872 proteins were identified, quantified, and 
used for statistical analysis across the longitudinal patient cohort. In response to TB treatment, 244 
proteins were significantly altered. Pathway/network comparisons helped visualize the 
interconnected proteins, identifying up regulated (lipid transport, coagulation cascade, 
endopeptidase activity) and down regulated (acute phase) processes and pathways in addition to 
other cross regulated networks (inflammation, cell adhesion, extracellular matrix). Detection of 
possible lung injury serum proteins such as HPSE, significantly downregulated upon treatment. 
Analyses of microbiologic data over time identified a core set of serum proteins (TTHY, AFAM, 
CRP, RET4, SAA1, PGRP2) which change in response to treatment and also strongly correlate 
with culture status. A similar set of proteins at baseline were found to be predictive of week 6 and 
8 culture status.
Conclusion: A comprehensive host serum protein dataset reflective of TB treatment effect is 
defined. A repeating set of serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2, among 
others) were found to change significantly in response to treatment, to strongly correlate with 
culture status, and at baseline to be predictive of future culture conversion. If validated in cohorts 
with long term follow-up to capture failure and relapse of TB, these protein markers could be 
developed for monitoring of treatment in clinical trials and in patient care.
Keywords
Ion mobility spectrometry; Proteomics; Tuberculosis; Antibiotic treatment
1. Introduction
Tuberculosis (TB) is the leading cause of death from a single infectious agent [1]. According 
to the WHO, an estimated 10.4 million people fell ill with TB in 2016 with most of the 
incidents concentrated in developing countries [1]. Sputum-based culture remains the gold 
standard for monitoring response to treatment in clinical practice as well as in clinical trials 
[2–4]. Despite its long history in TB drug development, 8-week culture status and culture 
conversion as a measure of bacterial burden has limitations. First, the reliance on sputum is 
limiting given sputum production decreases rapidly on treatment. Additionally, analyses of 
performance of treatment culture conversion for predicting long term outcomes have shown 
variable results [5–7]. As a consequence, there has been a call for the development of new 
quantitative, non-sputum, nonculture-based TB biomarkers. If proven accurate and 
predictive, a blood-based biomarker signature would facilitate middle and phase 2 
development for new TB drugs and regimens, as well as provide information on individual 
response to treatment.
Recent technologic advances in mass spectrometry (MS) based proteomics now provide 
multiple, robust tools that allow for high-accuracy, high-throughput analysis of clinical 
samples [8,9]. As a result, a better depth of coverage with accurate quantification can be 
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obtained for a global proteome in complex clinical specimens. To date, discovery-based 
proteomics has primarily concentrated on investigating protein biomarkers of infection for 
early diagnosis of TB [10]. Early surface-enhanced laser desorption/ionization (SELDI) 
platforms compared serum samples from active TB patients with uninfected controls to 
identify possible discriminatory protein profiles, with recent studies involving a more in-
depth separation [11,12]. Additionally, several liquid chromatography-mass spectrometry 
(LC-MS/MS) based platforms have been used as well to perform this comparison, providing 
a complimentary list of differentiated host proteins [13,14]. Achkar et al., presented a more 
comprehensive diagnostic study using LC-MS/MS and multiple-reaction monitoring (MRM) 
based assay to identify panels of host proteins that can distinguish active TB from latent 
infections as well as other respiratory disorders [15]. Longitudinal studies of TB treatment 
and response have also been conducted using aptamer array-based methods applied to small 
cohorts of patients [16–18].
In the present study we evaluate treatment response through the use of a sensitive MS 
platform, with the addition of ion mobility separations (IM) to an LC-MS platform, 
providing a more robust and higher throughput discovery analysis pipeline capable of larger 
scale clinical study investigations [19]. We assayed a large collection of serum samples 
collected at baseline and after 8 weeks of treatment from participants enrolled in a phase 2 
clinical trial comparing rifapentine to rifampin, as part of combination therapy [20]. In this 
study, we sought to provide an unbiased characterization of the serum proteome in TB 
patients undergoing treatment, evaluating associations with clinical and microbiologic 
characteristics, comparing changes in protein biomarkers relative to culture status at time 
points 2, 4, 6 and 8 weeks during treatment, with the objective of identifying a serum protein 
signature indicative of treatment effect.
2. Materials and methods
2.1. Study population
CDC TB Trials Consortium (TBTC) Study 29 (ClinicalTrials.gov Identifier NCT00694629) 
is a prospective, multicenter, open-label Phase 2 clinical trial comparing the antimicrobial 
activity and safety of standard daily regimen containing rifampin, to that of the experimental 
regimen with daily rifapentine (10 mg/kg/dose), both given with isoniazid, pyrazinamide and 
ethambutol to adults with smear positive, culture-confirmed pulmonary TB. The primary 
efficacy endpoint of the trial was the proportion of patients, by regimen, having negative 
sputum cultures at completion of 8 weeks (40 doses) of treatment. All TB treatment was 
administered 5 days/week for 8 weeks and directly observed. All participants underwent 
HIV testing. Cultures were performed using both Lowenstein-Jensen (LJ) solid media 
(inoculum volume, 0.2 mL) and BACTEC mycobacterial growth indicator tube (MGIT, 
Becton Dickinson and Co, Franklin Lakes, New Jersey) liquid media (inoculum volume, 0.5 
mL) with the MGIT 960 system, and assessed for presence of M. tuberculosis. Additional 
information regarding the design, conduct, and results of TBTC Study 29 has been published 
[20].
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2.2. Selection of participants
Out of a total of 531 participants in the parent trial, we included 289 consecutively enrolled 
protocol-correct participants from CDC-TB Trials Consortium clinical trials sites in North 
America, South Africa, Uganda, and Spain, for this sub-study. The 289 participants included 
in the proteomic analyses had sputum smears positive for acid fast bacilli at baseline and 
were culture positive for drug-susceptible pulmonary TB. Detailed demographic, clinical, 
radiographic and microbiologic data were collected using CDC-TBTC developed case report 
forms as part of the parent clinical trial.
2.3. Sample processing
Serum was collected, processed and stored at baseline (time of enrollment), and after 8 
weeks (40 doses) as previously described [20], in a standardized manner according to a 
manual of operating procedures. The investigators conducting LC-IM-MS assays were 
blinded to all patient characteristics until after assay results were submitted to the TBTC 
Data and Coordinating Center. Individual human serum samples were partitioned and 
depleted of 14 specific highly abundant proteins using a ProteomeLab™ 12.7 × 79.0-mm 
human IgY14 LC10 affinity LC column (Beckman Coulter, Fullerton, CA), which was 
performed using the manufacturer’s instructions to disrupt protein-protein binding and 
capture of additional proteins. Further processed of the flow-through portion of the depletion 
included automated protein isolation, denaturation, tryptic digestion, and peptide isolation 
[19].
2.4. LC-IM-MS analysis
Analysis of processed serum samples was performed on an in-house built instrument that 
couples a 1-m ion mobility separation with an Agilent 6224 TOF MS upgraded to a 1.5 m 
flight tube [19] coupled with LC and including a fully automated in-house built 4-column 
HPLC system equipped with in-house packed capillary columns [21]. A 60-min gradient 
with shorter columns (30 cm long with same dimensions and packing) was used with the 
IM-MS platform and data were collected from 100 to 3200 m/z. This unique platform has 
been previously described in detail [19,22], and has been optimized for higher throughput 
larger scale clinical sample analysis as it provides the benefit of the inclusion of an 
orthogonal ion mobility separations for depth of coverage coupled with a reduced LC 
separations component for faster overall analysis times (60 min per sample).
2.5. Data processing
Identification and quantification of the detected peptide peaks was performed utilizing the 
Accurate Mass and Time (AMT) tag approach [23]. Briefly, three pooled human serum 
samples were created (baseline, 8 weeks negative culture status, 8 weeks positive culture 
status) and divided into 24 fractions each using HPLC high pH fractionation. LC-MS/MS 
was performed on each fraction using the LTQ Orbitrap Velos MS and a reverse phase low 
pH LC separation [19]. A subsequent AMT tag database was created as previously described 
[24,25]. All MS/MS data can be obtained at ProteomeXchange under identifier PXD009029. 
Multiple in-house developed informatics tools (publicly available http://omics.pnl.gov/
software) were used to process the LCMS data and correlate the resulting LC-MS features to 
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an AMT tag database that contained accurate mass, LC separation elution time, and IMS 
drift time information for peptide tags generated from serum proteins. Among the tools used 
were algorithms for peak-picking and for determining isotopic distributions and charge 
states [26]. Further downstream data analysis incorporated all possible detected peptides into 
a visualization program, VIPER, to correlate LC-MS features to the peptide identifications 
in the AMT tag database [27].
2.6. Statistical analysis
Peptide values were log2 transformed and normalized for occurrence filtering and outlier 
removal as previously described [19]. Protein values were generated from the processed 
peptide level data utilizing the R roll-up approach as previously described [19]. All analyses 
were performed in the R environment, version 3.3.3. Linear mixed models were fit using the 
lme4 package in R. Contrasts were estimated using the package lsmeans in R (R Project for 
Statistical Computing, http://cran.r-project.org). Pathway enrichment statistics were 
calculated using a log-rank test on proteins that were ordered by significance level within 
each contrast. To determine which demographic, clinical, radiographic and microbiologic 
variables may drive protein expression during model building, univariate regressions or 
ANOVAs were assessed. Redundancy amongst variables was assessed using Spearman’s 
correlations of the variables themselves, as well as correlations calculated using protein 
abundance values, which shows the cross correlations of relevant clinical and demographic 
variables as well as bar plots, after only site/region adjustment, showing the number of 
significant proteins associated with each variable based upon the serum proteome results. 
Once the primary drivers of protein expression were determined, separate linear mixed 
models were fit to investigate the influence of culture conversion on protein expression in 
response to treatment (with adjustment for baseline disease severity). Baseline disease 
severity was determined by chest radiograph classification of cavitation status. All models 
adjusted for patient and study site as random effects, and the following fixed effects: 
geographic region, age, body mass index, sex, and HIV status.
Criteria to identify significantly different proteins included p-value < 0.05, minimum ± 0.1 
log2 abundance change between comparisons and quantified in at least 50 patient pairs per 
protein. Samples without quantitative protein information were treated as missing data and 
not included for that particular protein analysis. Immunoglobulin constant region proteins 
and other immunoaffinity depleted proteins were excluded as described previously [19]. 
Pathway mapping was performed utilizing GO annotations extracted from DAVID version 
6.8 (https://david.ncifcrf.gov/) using the ontology for biological process 
(GOTERM_BP_DIRECT). Bonferroni correction for only those GO term pathways that had 
a p value < 0.05 were selected. Cytoscape version 3.5.1 was used to create the 
interconnections of the pathway networks.
2.7. Ethics statement
Study 29 was approved by both CDC and local institutional review boards, and written 
informed consent was obtained from all study participants for collection of serum for TB-
related research. The institutional review board at University of California, San Francisco 
approved this biomarker study (UCSF IRB Number: 12–10360).
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3. Results
3.1. Study population and serum proteins identified
A schema of the proteome study is provided in Fig. 1. Table 1 shows the clinical metadata of 
the 289 study participants from whom serum was collected and LC-IM-MS high-throughput 
analysis applied. In total, 10,137 peptides corresponding to 872 proteins were identified, 
quantified, and used for statistical analysis across the longitudinal patient cohort 
(Supplemental Table 1).
3.2. Treatment effect on serum protein abundances
A linear mixed model, fit to investigate the outcome associated with treatment effect of each 
serum protein abundance over time, identified 244 serum proteins deemed significantly 
changing after 8 weeks of treatment (Fig. 2A and Supplemental Table 2). A heat map of the 
244 serum proteins identified, where values represent the quantitative change in protein 
abundance between baseline and 8 weeks per protein, is shown in Fig. 2B. Observed are 
subsets of proteins which are quantitatively differentiated in the serum due to either up (red) 
or down (blue) regulation upon treatment. The majority of protein alterations are upregulated 
upon treatment (138 out of 244). Network and pathway interaction mapping of these 
treatment related proteins identified interconnections of multiple pathway networks and their 
response after 8 weeks of treatment (Fig. 3). In addition to acute phase proteins, pathway 
networks emerged for lipid transport and metabolism; complement cascade; proteolysis; 
coagulation cascade; inflammation and defense; and cell adhesion and extracellular matrix, 
among others.
3.3. Serum protein signatures and culture conversion
By utilizing the same comparison model described above, patient serum protein results were 
divided and analyzed based upon either positive or negative culture status for a particular 
time point to determine protein significance. Looking at week 2 culture status stratifications, 
CRP and many other highly downregulated proteins (SAA1, A1AG1) have reduced fold 
change differences for patients who have quickly converted at week 2 compared to week 8 
stratifications where such proteins have similar or greater fold change differences between 
positive and negative stratification (Supplemental Table 3). Investigation of patients who 
remain culture positive after 8 weeks of treatment utilized the same model as previous but fit 
the outcome to culture status stratification at either 6 or 8 weeks of treatment. Fig. 4A and B 
shows the volcano plots of the week 8 and week 6 culture results respectively. Overall, we 
identified 41 and 54 proteins for week 8 and week 6 culture status respectively whose 
baseline to end of intensive phase biomarker changes were significantly differing between 
culture-negative and culture-positive patients. Fig. 4C shows the overlap between each 
comparison and the original 244 treatment effect serum proteins. Whereas these culture-
status comparisons are statistically less significant, the 17 proteins which are consistently 
discriminatory for both week 6 and 8 culture status stratifications provide a promising list to 
explore further as predictive markers of culture conversion. (Fig. 4A and B and 
Supplemental Table 4).
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3.4. Baseline serum proteins predictive of culture status
Seventeen proteins were identified with concentrations at baseline that were associated with 
culture conversion status with a p < 0.001 at any time point stratification (Supplemental 
Table 5). Across all culture time points, these seventeen proteins were most discriminatory 
for the week 6 culture status. The top six baseline proteins that discriminate culture status at 
subsequent time points are shown in Fig. 5, and all overlap with those identified as 
significant in fold change comparisons from baseline to week 8.
4. Discussion
In this study, we identified a network of interconnected proteins and pathways representing 
the host response to TB treatment over 8 weeks that were differentially expressed in relation 
to culture conversion status. A total of 244 proteins were significantly altered in response to 
8 weeks of intensive phase therapy. Pathway and network comparisons identify proteins that 
during treatment are up regulated (coagulation cascade, endopeptidase activity, lipid 
transport), with other proteins down regulated (acute phase), in addition to other cross 
regulated networks (inflammation, cell adhesion, extracellular matrix) (see Supplemental 
Tables 1 and 2). Across pathways and network comparisons, we discuss below selected 
proteins specifically associated with lung injury, bacterial load, and/or pulmonary bacterial 
infection in the published literature, in addition to proteins that are noted to be unique in 
terms of proteomic discovery outputs. The most significant changes between baseline and at 
8-weeks of treatment occurred for proteins that were upregulated at the time of diagnosis 
and decreased significantly after treatment, predominated by acute phase reactants. 
Numerous proteins from coagulation and complement cascade pathways were also 
differentially expressed after treatment, including anti-coagulation proteins endothelial 
protein C receptor (EPCR) [28], plasma serine protease inhibitor (IPSP), alpha-2-
macroglobulin (A2MG), coagulation factor XII (FA12) [29] and hyaluronan-binding protein 
2 (HABP2), which aids in fibrinolysis [30] and prevention of fibrin clots formation by acting 
as an inhibitor of coagulation [29]. Additional coagulation-associated proteins included 
antithrombin III (ANT3) which participates in inhibition of several procoagulants [31], 
phosphatidylethanolamine-binding protein 1 (PEBP1) a serine protease inhibitor that inhibits 
thrombin, and Beta-2-glycoprotein 1 (APOH) and vitamin K-dependent protein C (PROC) 
that degrades factor V and VIII [32], further preventing formation of clots. Coagulation 
associated proteins that decreased with treatment were fibrinogen alpha chain (FIBA), factor 
IX (FA9), platelet factor 4 variant (PF4V) and vitamin K dependent protein S (PROS). 
Finally, we observed down-regulation of Ficolin-2 (FCN2), which acts as an opsonin that 
facilitates bacterial elimination via the complement cascade [33].
Several proteins involved in immune modulation and airway defense were also identified as 
differentially expressed, notably two antibacterial proteins that decreased with treatment: 
neutrophil defensin1 (DEF1) and platelet basic protein (CXCL7). Ashitani et al. reported an 
increased concentration of alpha-defensins in plasma of patients with active TB where the 
concentration of defensins reduced after 8 weeks of treatment [34]. Kalita et al. reported that 
human neutrophil peptides (HNP)s in conjugation with anti-TB drugs resulted in significant 
clearance of bacterial load [35] where the lower concentration post treatment is likely due to 
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a decreased bacterial load. CXCL7, produced by human phagocytes, has been proposed to 
have a significant influence on the immune response against mycobacterial infection [34] 
and LYSC has been known to have bacteriolytic properties - both proteins decreased 
significantly during treatment. We also identified down-regulation of protein ATP-binding 
cassette sub-family A member 3 (ABCA3), which acts in the formation of pulmonary 
surfactant by transporting lipids [36]. Pulmonary surfactants provide alveolar stability by 
lowering surface tension at the air-liquid interface and also serve a direct anti-microbial role 
[37]. The presence of ABCA3 in the blood serum is interesting, and the down regulation 
may provide a blood marker of decreasing bacterial load. Two other proteins, cystatin C 
(CYTC), a potent inhibitor of the proteolytic activity of cysteine cathepsins that drive lung 
fibrosis [38–40], and selenoprotein P (SEPP1) reported to have antioxidant properties [15], 
were upregulated after 8 weeks of treatment.
Cavitation in pulmonary TB results in degradation of structural fibers and extracellular 
matrix (ECM) protein components [41], which can provide altered protein signatures in 
serum. We identified several likely ECM protein markers for further investigation. Fibrillar 
type I collagen in ECM is responsible for providing the tensile strength in lung tissues [41]. 
It has been reported that Mtb induces an increased expression as well as secretion of matrix 
metalloproteinase (MMP-1), which has been reported to increase following bacterial 
infection [42]. Metalloproteinase inhibitor-1 (TIMP-1) is an inhibitor of MMP-1 [42], and in 
our study, we found TIMP-1 decreased following treatment in conjunction with increasing 
MMP secretion. As cavitation resolves during treatment, upregulation of matrix and cell 
adhesion proteins that are involved in the repair process of the ECM of lung tissue is 
expected. Indeed, we found matrix proteins upregulated after treatment, including neural cell 
adhesion molecule L1-like protein (NCHL1) which facilitates cell-cell or cell-matrix 
interactions [43], lumican (LUM) known to regulate ECM’s function such as tissue 
hydration and collagen fibrillogenesis [44], fibronectin (FINC), which binds to integrins 
promoting cellular adhesion [45], laminin subunit beta-1 (LAMB1), an ECM protein, 
collagen alpha-1 chain (CO1A1), a major structural components of the lung [42], as well as 
gelsolin (GELS) and talin (TLN1) both involved in cell-matrix interactions [18,46].
Several proteases and peptidases were differentially regulated on treatment with a majority 
of peptidases and proteases up-regulated. Fetuin A (FETUA) enhances phagocytosis of 
apoptotic cells, and has been reported to decrease in whole blood samples of patients with 
active TB [47]. Olivier et al., found that both Fetuin A and Fetuin B (FETUB) are negative 
markers of acute phase reaction. We saw a similar trend, as both these peptidases were 
downregulated in patients at baseline and increased significantly post treatment [48]. Inter-
alpha-trypsin inhibitor heavy chain (ITIH-H1 and H2) is known to contribute to extracellular 
matrix stability by covalently binding to hyaluronic acid [49]. This is in line with their 
upregulation post treatment. N-acetylmuramoyl-L-alanine amidase (PGRP2) was also up-
regulated, likely due to its role in digesting biologically active bacterial peptidoglycan into 
inactive fragments [50]. In contrast, heparanase (HPSE) was down-regulated post-treatment. 
Heparanase is an endoglycosidase which cleaves heparan sulfate proteoglycans for 
extracellular matrix degradation and remodeling [51]. Among other functions, recent reports 
have it associated with acute lung injury [52], where heparanase was associated with loss of 
heparin sulfate in glycocalyx degradation, leading to neutrophil adherence and 
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inflammation. Inhibition of heparanase prevented neutrophil adhesion and attenuated sepsis 
induced acute lung injury in mice [52]. In humans, heparanase was observed higher in 
abundance in lung biopsies with alveolar damage as well as higher plasma heparan sulfate 
degradation activity [53]. Identification and quantification of heparanase in the serum is 
significant as it groups with the acute phase markers of infection, and possibly provides a 
lung specific marker reflecting lung tissue damage and recovery.
Consistent with other reports [33], several lipid transport proteins were significantly 
upregulated after treatment. Hypocholesterolemia has been reported in TB patients [54], and 
it has been proposed that Mtb may derive carbon and energy from cholesterol [55]. Other 
lipoproteins with anti-inflammatory properties, namely platelet-activating factor acetyl 
hydrolase (PAFA) and phosphatidylcholine-sterol acyltransferase (LCAT) were also up-
regulated with treatment. Binding proteins also provide indication of nutritional status and 
were down-regulated at the time of diagnosis. Examples include corticosteroid binding 
protein (CBG), transthyretin (TTHY), serotransferrin (TRFE), insulin-like growth factor-
binding protein 3 (IGBP3) [56], albumin (ALBU) and tetranectin (TETN) and afamin 
(AFAM). Retinol binding protein (RET4) increased expression post-treatment might be due 
to retinoic acid’s ability to induce monocyte differentiation [42]. This helps in inhibition of 
bacterial proliferation in macrophages, thus further reducing the bacterial load [42]. TETN 
binds plasminogen, increasing its activity and resulting in more plasmin formation 
promoting fibrinolytic activity [57]. Afamin as a vitamin E binding protein is reduced at 
baseline likely due to a known decrease in concentration of antioxidants in TB infections 
[58]. Conversely, upregulation of Thyroxine binding globulin (THBG) upon treatment may 
be attributed to the hepatic effect of the use of rifamycins in the regimens studied in the 
parent trial [59]. Regarding drug effects, we found sex hormone-binding globulin (SHBG) to 
be significantly increased on treatment. Rifamycins have been shown to increase the 
expression of SHBG [60]. This is proposed to be due to the induction of cytochrome P450 
mediated monoxygenase activity, which is believed to be a rate limiting step in the synthesis 
of testosterone and estrogen from cholesterol through pregnanolone [60]. As a result of the 
increase synthesis of these androgens, SHBG expression increases proportionally as well.
Utilizing culture status conversion data through 8 weeks, the change in protein serum 
concentrations over this timeframe provided mechanistic insights when correlating how 
quickly (or slowly) patients recover from TB disease. We observed a consistent set of 
proteins that represent a signature of a slower response to treatment (Fig. 4C). We focused 
on proteins which were consistently discriminatory for both 6 and 8 weeks of culture status 
stratification as these two time points represent the inflection point where the majority of 
patients convert from positive to negative. Interestingly, regardless of the time point 
stratification, the majority of these proteins overlap with those previously identified in the 
overall treatment effect changes, 17 proteins, implying they are associated with treatment or 
disease resolution. Each of these proteins has the same directionality of change regardless of 
time point stratification, see Supplemental Table 4. This suggests an overall delay in 
recovery response for those patients remaining culture positive at week 6 through week 8. 
Specifically, all acute phase proteins in this list, CRP, A1AT, A1AG1, A1AG2, SAA1, have 
lower fold changes for culture positive patients compared to culture negative patients at both 
week 6 and week 8, Supplemental Table 3. These proteins are the most reduced in 
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abundance due to treatment and that reduction is attenuated for those still culture positive at 
these later time points. Similarly, proteins heparanase (HPSE) and DEF1 were also highly 
downregulated in treatment and showed diminished downregulation in culture positive 
individuals. The changes in heparanase abundance, which infers correlation with lung injury, 
has the potential to provide a unique specific serum marker of lung injury/and recovery in 
Mtb patients. Conversely, lipid transport proteins (APOA4, APOH), binding proteins 
(TTHY, AFAM, RET4), as well as protease PGRP2 were seen as upregulated overall due to 
treatment and disease resolution but this upregulation was diminished in patients still culture 
positive at 6 and 8 weeks. Though these proteins consistently correlated with disease 
severity and resolution, how predictive they are in regard to relapse cases will need further 
investigation.
An evaluation of baseline protein values in the serum identified a core set of proteins which 
correlated well with future culture conversion. Many of these proteins overlap with our 
treatment effect analyses, suggesting that for these particular proteins, the initial protein 
abundance at baseline appears to relate to their change in abundance in regard to patient 
culture status conversion, and hence can provide an important initial baseline indicator of 
treatment efficacy. Baseline values of proteins TTHY, AFAM, CRP, and PGRP2 showed the 
greatest differentiation, however we did see variations in predictive ability across the week 
stratifications. CRP differentiated best in early time points but gradually reduced out to week 
8. Interestingly, TTHY, AFAM, and PGRP2 showed increased discrimination at week 6. It is 
somewhat unclear as to why, however it does appear to be driven by a drop in the remaining 
culture positive patients. Week 6 also had the most balanced stratification between culture 
positive/negative patients. The Study 29 serum sample set used in our study was also 
evaluated using directed immunoassays for a pre-selected panel of biomarkers, focusing 
primarily on biomarkers of inflammation and immune response [61]. We saw overlap in 
markers that were significantly modulated by treatment (CRP, SAA, MMP-1, TIMP-1) and 
in the biomarkers associated with early conversion (CRP). The non-directed MS approach 
used in the current study, however, was able to identify additional pathways than were found 
using the directed approach.
Our study has limitations. First, long-term outcomes of interest (relapse versus durable cure) 
were not a component of the parent phase2 trial, and our analyses were focused on 
biomarker associations with baseline severity and microbiologic indicators of treatment 
effect only. An evaluation of the most promising biomarkers we discovered should be 
pursued as part of clinical trials with long-term follow-up. Second, we were limited in our 
ability to explore the dynamics of biomarker change given two time points for serum 
collection. An assessment of the best performing markers in our study, across additional 
time points would improve our understanding of the predictive performance of these 
biomarkers. Third, the parent trial allowed for TB treatment prior to the randomization visit 
when serum was collected and study drugs initiated. This may have impacted baseline 
biomarker levels, however, in sensitivity analyses limited to participants with no pre-
treatment, the biomarkers with the strongest associations with baseline severity and 
treatment effect remained the same.
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In sum, we provide a comprehensive host serum protein dataset reflective of TB treatment 
effect. A core set of core serum proteins (TTHY, AFAM, CRP, RET4, SAA1, PGRP2, 
among others) were found to change significantly in response to treatment, to strongly 
correlate with culture status, and at baseline to be predictive of subsequent culture 
conversion. The protein signatures identified here have the potential to be informative of 
disease resolution throughout the treatment time course. If validated in cohorts of patients 
with longer treatment and follow-up, the proteins identified may serve as blood-based 
markers of treatment effect with applications in clinical care and clinical trials.
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Fig. 1. 
Schematic workflow of the experimental design and analysis procedure. Utilization of the 
LC-IM-MS platform generated peptide level peak intensity data for each of the 578 samples 
(289 baseline samples and 289 8-week samples) from which protein level data was inferred. 
Protein level data was the basis to investigate the dynamic changes in the serum proteome 
after 8 weeks of treatment.
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Fig. 2. 
Visual representation of the serum proteins differential abundant due to 8 weeks of antibiotic 
treatment. A) Volcano plot of all proteins analyzed via linear mixed model to determine 
differential abundance due to antibiotic treatment at 8 weeks. Red lines correspond to 
thresholds of acceptance (pval < 0.05 and > ±0.1 log2 fold change). B) Heat map of 244 
proteins representing quantitative changes in protein abundances between baseline and 8 
weeks from 289 patients. Red magnitude representing increase in abundance with treatment, 
blue magnitude representing reduced serum abundance upon treatment. (For interpretation 
of the references to colour in this figure legend, the reader is referred to the Web version of 
this article.)
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Fig. 3. 
Protein based pathway mapping of the patient response in the serum to antibiotic treatment. 
The GO annotations of 244 significantly altered proteins were extracted from DAVID and 
after corrected p-value filtering was visualized in Cytoscape to create the interconnected 
pathway network. Yellow squares: Pathways, spatial proximity indicates similarity in 
pathways; Red circles: proteins upregulated following 8 weeks of therapy; Blue circles: 
proteins downregulated following 8 weeks of therapy. Color intensity represents degree of 
fold change, darker signifying larger fold change. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the Web version of this article.)
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Fig. 4. 
Plots and diagram of proteins significantly altered based upon culture status at week 6 and 
week 8 treatment. Volcano plot showing log2 values calculated from the difference of fold 
change from baseline to week 8 for culture positive (culture+) patients compared to culture 
negative (culture-) patients at (a) Week 6 culture status and B) Week 8 culture status based 
upon a linear mixed model. Proteins labeled are those most significant and found in common 
across both week 6 and week 8 results. C) Venn diagram representing overlap between the 
244 treatment serum proteins and discriminatory proteins for week 6 and week 8 culture 
status stratification.
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Fig. 5. 
Plots of 6 serum proteins measured at baseline with highest significance in discriminating 
subsequent culture status across all culture time points. Black dots represent the average 
log2 protein abundance for that protein, red error bars (standard deviation) represent positive 
culture status patients, where green error bars represent patients with negative culture status. 
(For interpretation of the references to colour in this figure legend, the reader is referred to 
the Web version of this article.)
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